Why good products with real capital still end up worth nothing

I get called into companies after the interesting part is over. By the time someone hands me a data room, the story has usually already been written; I'm just the first person willing to read it out loud.

There's a version of this story I see more than any other. It goes like this:

A founder solves a genuinely hard problem and creates a category that didn't exist. The product is good; not marketing-good, actually good. It wins awards. It gets press. It lands national retail placement. The founder recruits an executive team with real résumés from real brands. Competitors show up and copy the idea, which everyone treats as validation.

And after more than a decade in business and eight figures of invested capital, the company has never had a profitable year, has never had a profitable market, and is raising again.

Nobody in this story did anything stupid. That's what makes it worth studying. Every individual decision was defensible. The failure was structural, and it was visible years before anyone acted on it.

Distribution gets mistaken for traction.

Retail placement is the easiest thing in consumer goods to raise money against and the hardest thing to monetize. A slide with national retailer logos on it will close a round. It will not fill a P&L.

So the company optimizes for door count, because door count is what investors ask about. Meanwhile, the number that actually determines survival revenue per door, per month quietly declines year after year, because the best accounts get signed first and everything after that is a worse account than the one before it.

Eventually you have a footprint that looks like an asset and behaves like a liability. Below a certain velocity, a retail listing isn't distribution; it's a pending delisting that you'll pay for twice, once in unsold inventory and once in reverse logistics.

The cost structure never gets interrogated.

Some businesses carry two expensive structural regimes at the same time. Cold chain and regulated distribution. Perishability and licensing. Heavy freight and thin margin. Each one alone is survivable. Stacked, they can consume the entire gross margin before anyone reaches the operating line.

When that happens, there is no volume at which the business converges to profit. Scaling a negative contribution margin faster doesn't fix it; it accelerates the loss. This is the single most important sentence in any turnaround, and it is the one that five-year models are built specifically to avoid confronting.

The growth test runs, fails, and gets ignored.

At some point, the company raises enough to properly fund a go-to-market push. Real budget, real operators, real duration. This is the experiment that answers whether spend converts to revenue.

Often the answer comes back negative; sometimes revenue actually declines the following year. That is not a disappointing quarter. That is the business telling you, with evidence, that the engine doesn't work as configured.

The correct response is to restructure: cut to a contribution-positive core, keep only the markets and accounts that clear their own costs, and rebuild from there. The common response is to cut the spend but keep the structure — same national footprint, same channel strategy, same growth narrative for the next raise. The company gets quieter without getting healthier.

Debt gets used as operating capital.

Notes and loans raised to cover operating losses convert a solvable operating problem into an unsolvable balance sheet problem. The debt didn't buy a plant or a distribution network. It bought time, and it now has a permanent senior claim on every dollar of margin the business will ever produce.

There's a line worth watching: once annual interest expense approaches a meaningful fraction of gross profit, every operational improvement you make accrues to the lender. The operators are working for free. The equity is already gone — it just hasn't been marked yet.

This is the part people miss, and it's the part I care most about.

The failure usually isn't that the company raised too much. It's that it raised in the wrong shape.

Picture a business that raises roughly a million dollars a year, every year, for nine or ten years, while burning slightly more than that. Add it up, and it's a substantial number; the kind of number that should have bought a real business. But no single round was ever large enough to fund the test that mattered.

Three things follow, every time:

The CEO becomes a full-time fundraiser. Half the founder's calendar goes to capital instead of customers. The operating problems that created the need to raise never get solved, because the one person best positioned to solve them is on a plane.

No round funds a real answer. A twelve-month bridge buys twelve months of survival. It does not fund a regional saturation play, a manufacturing renegotiation, or a distribution model rebuild the things that would actually determine whether the business works. So the company keeps buying time instead of buying information.

The cap table becomes uninvestable. A decade of small rounds leaves founders with a minority position, hundreds of investors to manage, and a preference stack sitting on top of negative book equity. Any serious institutional buyer now has to clean up ten years of accumulated structure before writing a check. Most will pass rather than do that work — not because the business is bad, but because the paperwork is.

One properly sized round early, deployed against a disciplined regional thesis, beats the same total capital delivered in annual installments. Same money. Completely different outcome. The increments are the problem.

These are available in real time. None of them require hindsight.

Prove one market before entering the second. Saturate a single metro. Reach positive contribution margin at the market level, including allocated freight and salesforce, before replicating. Going national early without a single profitable market is how a company ends up with scale it can't afford.

Solve the structural cost problem before scaling the SKU. If your cost-to-serve is eating your gross margin at low volume, that demands an answer up front: regional production near demand, a partner model that pushes the expensive part onto someone with existing density, or a product line extension that carries the overhead. None of these are cheap. All of them are cheaper than a decade of losing money on every unit.

Kill the growth narrative when the growth test fails. When a properly funded go-to-market push produces flat or declining revenue, that's your answer. Restructure. Don't raise again on the same thesis.

Never let debt service consume your margin. Set the threshold in advance and treat crossing it as a governance event, not a footnote.

Raise once, properly, or don't raise. If you can't raise enough to fund the actual test, the answer is to shrink to profitability, not to bridge. Bridges to nowhere are still bridges you have to pay for.

Four paths, in rough order of likelihood:

Continue. Raise the next increment from the existing base, extend twelve to eighteen months, repeat. This is what usually happens, and it's why the loss column keeps growing.

Strategic sale. A larger player buys the formulation, the regulatory pathway, the registrations, and the brand and folds it into infrastructure that already has the expensive parts built. Where a company spent years solving a genuinely hard technical or regulatory problem, that work has real value in the right hands. This is often the highest-probability good outcome, and it rarely returns capital to common.

License it. Keep the brand, license manufacture and distribution to a partner with existing density, collect a royalty. Low ceiling, but it converts a cash-consuming business into a cash-producing one almost overnight.

Recapitalize. New money comes in senior, existing preferences get compressed or wiped, the balance sheet gets cleaned, and the company gets a focused regional mandate. This is the only path that preserves the business as a going concern. It requires existing holders to accept that their position is already worth roughly zero, which most cap tables won't do until the wire is about to fail.

Distribution is not traction. Traction is repeat velocity in a channel where the unit economics work. Everything else is a logo slide.

Category creation is a cost until someone else validates it. Being first only matters if you convert the head start into structural advantage. Hard-won regulatory or technical expertise is an asset — license it, sell it, or build a moat with it. If you just absorb the cost and let imitators enter on top of your work, you paid for the category, and someone else will own it.

Fix contribution margin before you fix anything else. If you lose money on every unit at your current cost structure, growth is the enemy. Volume amplifies whatever sign is in front of your unit margin. The instinct to "grow into" the cost structure is how good products die.

A forecast without a mechanism is a wish. Ask one question of any projection: what specific, contracted, dated event causes the line to bend? "Increased market penetration" and "expanded distribution" are wishes. "A signed PO from a named account with committed volume starting in month three" is a forecast. When a model shows revenue tripling in a single month with no named cause, you're looking at arithmetic, not a plan.

The product works. The category is real. The team is credentialed. The brand has genuine equity with the customers who find it.

None of that is ever the problem.

The problem is that nobody — not the founders, not a decade of investors, not a board, not one of the checks that went in — ever forced the business to prove it could make money on one unit, in one store, in one city, before being asked to make money everywhere.

That question costs nothing to ask.

Not asking it costs everything.